Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose STZ mouse model of diabetes

Autoimmunity

Volumn 29, Issue 4, 1999, Pages 249-256

  Anastasi, E ^a   Dotta, F ^b   Tiberti, C ^b   Vecci, E ^b   Ponte, E ^b   Di Mario, U ^b  

^a DEM Foundation   (Italy)

^b NONE

Author keywords

Antigen; Diabetes; Insulin; Mice; Prevention; Streptozotocin

Indexed keywords

ANTIGEN; GLUCOSE; INSULIN; ISOPHANE INSULIN; MONOSIALOGANGLIOSIDE; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CELL ACTIVITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULITIS; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PROPHYLAXIS; STREPTOZOCIN DIABETES; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032963182     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939908994743     Document Type: Article

References (28)

1. Castano, L. and Eisenbarth, G.S. Type 1 diabetes: a chronic autoimmune disease of the human, mouse and rat. Ann. Rev. Immunol. 1990;8:647-679.
2. Riley, W.J., MacLaren, N.K., Krischer, J., Spillar, R.P., Silverstein, J.H., Schatz, D.A., Shwartz, S., Malone, J., Shah, S., Vadheim, C. and Rotter, J.I. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 1990; 323: 1167-1172.
3. Vardi, P., Crisa', L., Jackson, R.A., Herskowitz, R.D., Wolfsdorf, J.I., Einhorm, D., Linarelli, D., Dolinar, R., Wentworth, S., Brink, S.J., Starkman, H., Soeldner, J.S. and Eisenbarth, G.S. Predictive value of intravenous glucose tolerance test insulin secretion less or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991;34:93-102.
4. Palmer, J.P., Asplin, C.M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P.K. and Paquette, T.L. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339.
5. Harrison, L.C., Honeyman, M.C., DeAizpura, H.J., Schmidli, R.S., Colman, P.G., Tait, B.D. and Cram, D.S. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341: 1365-1369.
6. Dotta, F., Gianani, R., Previti, M., Lenti, L., Dionisi, S., D'Erme, M., Eisenbarth, G.S. and Di Mario, U. Autoimmunity to the GM2-1 islet ganglioside before and at the onset of the type 1 diabetes. Diabetes 1996; 45: 1193-1196.
7. Bonifacio, E., Bingley, P.J., Shattock, M., Dean, B.M., Dunger, D., Gale, E.A.M. and Bottazzo, G.F. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990; 335: 147-149.
8. Rabin, D.U., Pleasic, S.M., Shapiro, J.A., Yoo-Waren, H., Oles, J., Hicks, J.M., Goldstein, D.E. and Rea, P.M.M. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunol. 1994; 152: 3183-3188.
9. Castano, L., Russo, E., Zhou, L., Lipes, M.A. and Eisenbarth, G.S. Identification and cloning of a granule autoantigen (carboxypeptidase H) associated with type 1 diabetes. J. Clin. Endocrinol. Metab. 1991; 73: 1197-1201.
10. Shah, S., Malone, J. and Simpson, N.E. A randomized trial of intensive insulin therapy in newly diagnosed insulin dependent diabetes mellitus. N. Engl. J. Med. 1989; 320: 540-544.
11. Hramiak, I., Mahon, J., Finegood, D. and Dupre, J. Effect of short course of high dose insulin treatment in insulin dependent diabetes mellitus. Clin. Invest. Med. 1991: 14, 28A.
12. Chase, H.P., Butler-Simon, N., Garg, S., McDuffie, M., Hoops, S.L. and O'Brien, D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 444-446.
13. Elliott, R. and Chase, H. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362-365.
14. Godfredson, G.F., Busehard, K. and Frandsen, E.K. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes prone animals. Diabetologia 1985; 28: 933-935.
15. Atkinson, M.A., MacLaren, N.K. and Lucchetta, R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933-937.
16. Bowman, M.A., Campbell, L., Darrow, B.L., Ellis, T.M., Suresh, A. and Atkinson, M.A. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996; 45: 205-208.
17. Keller, R.J., Eisenbarth, G.S. and Jackson, R.A. Insulin prophylaxis individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927-928.
18. Eisenbarth, G.S., Verge, C.F., Allen, H. and Rewers, M.J. The design of trials for prevention of IDDM. Diabetes 1993; 42: 941-947.
19. Like, A.A. and Rossini, A.A. Streptozotocin-induced pancreatic insulitis. New model of diabetes mellitus. Science (Wash. DC) 1976; 193: 415-417.
20. Anastasi, E., Tiberti, C., Sensi, M., Ponte, E., Filippetti, R., Dotta, F., Vecci, E., Fiori, M.G. and Di Mario, U. Pancreatic gangliosides delay the onset of insulitis and hyperglycaemia in the low-dose streptozotocin mouse model. Scand. J. Immunol. 1993; 37: 308-313.
21. Sai, P., Elmansour, A., Audrain, M., Charbonel, B. and Bardet, S. Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow up study in type 1 (insulin-dependent) diabetic patients and in first degree relatives. Diabetologia 1993; 36: 778-784.
22. Svennerholm, L. and Fredman, P. A procedure for quantitative isolation of brain gangliosides. Biochem. Biophys. Acta 1980; 617: 97-109.
23. Williams, M.A. and McCluer, R.H. The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J. Neurochem. 1980; 35: 266-269.
24. Svennerholm, L. Chromatographic separation of human brain gangliosides. J. Neurochem. 1963; 10: 613-623.
25. Schnedl, W.J., Ferber, S., Johnson, J.H. and Newgard, C.B. STZ transport and cytotoxicity. Diabetes 1994; 43: 1326-1333.
26. Dotta, F., Previti, M., Nerman-Arbez, M., Dionisi, S., Cucinotta, D., Lenti, L., Di Mario, U. and Halban, P.A. The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not β-cell specific. Endorinology 1998; 189: 316-319.
27. Bjork, E., Kampe, O., Grawe, J., Halberg, A., Norheim, I. and Kalsson, F.A. Modulation of beta-cell activity and its influence on islet cell antibody (ICA) and islet cell surface antibody (ICSA) reactivity. Autoimmunity 1993; 16: 181-188.
28. Aaen, K., Rygaard, J., Jofensen, K., Petersen, H., Brogren, C.H., Horn, T. and Bushard, K. Dependence of antigen expression on functional state of beta-cells. Diabetes 1990; 39: 697-701.